• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

职业安全与健康管理局职业环境监督框架述评

Review of the OSHA framework for oversight of occupational environments.

机构信息

Division of Health Policy and Management at School of Public Health at University of Minnesota, USA.

出版信息

J Law Med Ethics. 2009 Winter;37(4):633-50. doi: 10.1111/j.1748-720X.2009.00437.x.

DOI:10.1111/j.1748-720X.2009.00437.x
PMID:20122106
Abstract

The OSHA system for oversight of chemicals in the workplace was evaluated to derive lessons for oversight of nanotechnology. Criteria relating to the development, attributes, evolution, and outcomes of the system were used for evaluation that was based upon quantitative expert elicitation and historical literature analysis. The oversight system had inadequate resources in terms of finances, expertise, and personnel, and insufficient incentive for compliance. The system showed a lack of flexibility in novel situations. There were minimal requirements on companies for data on health and safety of their products. These factors have a strong influence on public confidence and health and safety. The oversight system also scored low on attributes such as public input, transparency, empirical basis, conflict of interest, and informed consent. The experts in our sample tend to believe that the current oversight system for chemicals in the workplace is neither adequate nor effective. It is very likely that the performance of the OSHA oversight system for nanomaterials will be equally inadequate.

摘要

OSHA 对工作场所化学物质的监督系统进行了评估,以便为纳米技术的监督吸取经验教训。评估所使用的标准涉及系统的开发、属性、演变和结果,评估的基础是定量专家 elicitation 和历史文献分析。监督系统在财务、专业知识和人员方面资源不足,对合规性的激励也不够。该系统在新情况下缺乏灵活性。公司对其产品的健康和安全数据几乎没有要求。这些因素对公众信心和健康与安全有很大影响。监督系统在公众投入、透明度、经验依据、利益冲突和知情同意等属性方面的得分也较低。我们的样本中的专家倾向于认为,目前工作场所化学物质的监督系统既不充分也无效。OSHA 对纳米材料的监督系统的性能很可能同样不足。

相似文献

1
Review of the OSHA framework for oversight of occupational environments.职业安全与健康管理局职业环境监督框架述评
J Law Med Ethics. 2009 Winter;37(4):633-50. doi: 10.1111/j.1748-720X.2009.00437.x.
2
Commentary: Oversight of engineered nanomaterials in the workplace.评论:工作场所中对工程纳米材料的监督。
J Law Med Ethics. 2009 Winter;37(4):651-8. doi: 10.1111/j.1748-720X.2009.00438.x.
3
Evaluating oversight systems for emerging technologies: a case study of genetically engineered organisms.评估新兴技术的监督系统:以基因工程生物体为例。
J Law Med Ethics. 2009 Winter;37(4):546-86. doi: 10.1111/j.1748-720X.2009.00431.x.
4
Developing U.S. oversight strategies for nanobiotechnology: learning from past oversight experiences.制定美国纳米生物技术监督战略:从过去的监督经验中学习。
J Law Med Ethics. 2009 Winter;37(4):688-705. doi: 10.1111/j.1748-720X.2009.00441.x.
5
Using expert elicitation to prioritize resource allocation for risk identification for nanosilver.利用专家判断法对纳米银风险识别的资源分配进行优先级排序。
J Law Med Ethics. 2009 Winter;37(4):770-80. doi: 10.1111/j.1748-720X.2009.00447.x.
6
An integrated approach to oversight assessment for emerging technologies.新兴技术监督评估的综合方法。
Risk Anal. 2008 Oct;28(5):1197-220. doi: 10.1111/j.1539-6924.2008.01086.x. Epub 2008 Jul 9.
7
Evaluating oversight of human drugs and medical devices: a case study of the FDA and implications for nanobiotechnology.评估人类药物和医疗器械的监管:以 FDA 为例,兼论对纳米生物技术的启示。
J Law Med Ethics. 2009 Winter;37(4):598-624. doi: 10.1111/j.1748-720X.2009.00434.x.
8
Governance of nanotechnology and nanomaterials: principles, regulation, and renegotiating the social contract.纳米技术和纳米材料的治理:原则、监管和重新协商社会契约。
J Law Med Ethics. 2009 Winter;37(4):706-23. doi: 10.1111/j.1748-720X.2009.00442.x.
9
Federal government regulation of occupational skin exposure in the USA.美国联邦政府对职业性皮肤暴露的监管。
Int Arch Occup Environ Health. 2003 Jun;76(5):387-99. doi: 10.1007/s00420-002-0425-2. Epub 2003 May 29.
10
Gene therapy oversight: lessons for nanobiotechnology.基因治疗监管:纳米生物技术的教训。
J Law Med Ethics. 2009 Winter;37(4):659-84. doi: 10.1111/j.1748-720X.2009.00439.x.

引用本文的文献

1
Corporate social responsibility for nanotechnology oversight.纳米技术监管的企业社会责任。
Med Health Care Philos. 2011 Nov;14(4):407-19. doi: 10.1007/s11019-011-9330-3.